New hope for seniors with stubborn depression?

NCT ID NCT07623135

Recruiting now Symptom relief Sponsor: Eric Lenze Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests whether lumateperone (Caplyta) can help older adults (60+) whose depression hasn't improved with other treatments. One hundred participants will take either the drug or a placebo alongside their current antidepressant for 10 weeks. Researchers will measure changes in depression scores to see if the drug works better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lumateperone (Caplyta)
What this could lead to: If it works, this could offer a new option to help older adults with hard-to-treat depression feel better.
What could go wrong: This is a Phase 3 trial, but it's still early and small (100 people). The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER LATE LIFE DEPRESSION (LLD) TREATMENT RESISTANT DEPRESSION (TRD)

Contacts and locations

Locations

University of Arizona
NOT_YET_RECRUITING

Tucson, Arizona, 85713, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.